FRANKLIN LAKES, N.J.,
Oct. 5, 2020 /PRNewswire/
-- BD (Becton, Dickinson and Company) (NYSE: BDX), a
leading global medical technology company, today announced it has
received 510(k) clearance from the U.S. Food and Drug
Administration (FDA) for the BD FACSLyric™ Flow Cytometer with
the Integrated BD FACSDuet™ Sample Preparation System.
The new integrated system enables clinical laboratories to
fully automate the sample to answer process and improve their
efficiency by reducing errors and limiting the manual user
interactions required to run assays on the BD FACSLyric™ Flow
Cytometer.
The BD FACSDuet™ Sample Preparation System builds new
capabilities into the BD portfolio of clinical flow cytometry
solutions offering a pre-analytical system, that combined with the
BD FACSLyric™ Flow Cytometer is the first truly walkaway
sample-to-answer solution for clinical labs.
Physical integration between the BD FACSDuet™ Sample Preparation
System and the BD FACSLyric™ Flow Cytometer allows technicians to
load samples and reagents onto the BD FACSDuet™ Sample Preparation
System and obtain results once the samples are acquired and
analyzed on the BD FACSLyric™ Flow Cytometer. Data integration
using the BD FACSLink™ Middleware Solution offers bidirectional
communication between the instruments and connectivity with
laboratory information systems (LIS).
"Flow cytometry in the clinical lab is a complex process that
involves multiple workflows and manual steps. There is therefore a
need for lean and effective technologies to reduce lab costs,
increase quality and limit error rates. The BD FACSDuet™ Sample
Preparation System is the continuation of our 45-year history of
making reliable flow cytometry solutions that are robust, easy to
use and improve the clinical lab workflow," said Puneet Sarin, president of Biosciences at
BD.
Automation solutions for flow cytometry such as the BD FACSDuet™
and BD FACSLyric™ Complete Sample-to-Answer Solution helps to
improve accuracy and standardization from instrument-to-instrument
and operator-to-operator, enhancing throughput and providing
consistent results that clinicians depend on to inform patient
care.
The BD FACSLyric™ Flow Cytometer with the integrated BD
FACSDuet™ Sample Preparation System is now available as
an in vitro diagnostic (IVD) system in the United States as well as countries
recognizing the CE-IVD certification, which was achieved in
March 2019.
About BD
BD is one of the largest global medical technology companies in
the world and is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. The company
supports the heroes on the frontlines of health care by developing
innovative technology, services and solutions that help advance
both clinical therapy for patients and clinical process for health
care providers. BD and its 65,000 employees have a passion and
commitment to help enhance the safety and efficiency of clinicians'
care delivery process, enable laboratory scientists to accurately
detect disease and advance researchers' capabilities to develop the
next generation of diagnostics and therapeutics. BD has a presence
in virtually every country and partners with organizations around
the world to address some of the most challenging global health
issues. By working in close collaboration with customers, BD can
help enhance outcomes, lower costs, increase efficiencies, improve
safety and expand access to health care. For more information on
BD, please visit bd.com.
Contacts:
|
|
|
|
Kristen
Cardillo
|
Kristen
Stewart
|
BD Public
Relations
|
BD Investor
Relations
|
201-847-5657
|
845-642-1256
|
Kristen.cardillo@bd.com
|
Kristen.Stewart@bd.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bd-granted-fda-510k-clearance-for-bd-facslyric-flow-cytometer-with-newly-integrated-bd-facsduet-sample-preparation-system-301145263.html
SOURCE BD (Becton, Dickinson and Company)